News

Mylan announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch. Mylan received final…
Read More...

MabVax Therapeutics Holdings and Boehringer Ingelheim announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly…
Read More...

TRIGR Therapeutics, a US-based Biopharmaceutical company, and ABL Bio Corporation, a South Korean biotechnology company, jointly announced that it had entered into a binding agreement…
Read More...

Acceleron Pharma announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and…
Read More...

Jazz Pharmaceuticals announced a definitive agreement to sell its rights related to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in…
Read More...

Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer and other diseases, today announced the…
Read More...

Belgium-based global bio-pharmaceutical company UCB announced it has received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make…
Read More...

Eisai Co., Ltd and Biogen Inc announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's…
Read More...

Sorrento Therapeutics announced that it acquired the Sofusa lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, particularly, the…
Read More...

Juniper Pharmaceuticals announced that it has entered into a definitive agreement with Catalent, Inc. for Catalent to acquire all of the outstanding shares of Juniper at a price of…
Read More...

PIVOTAL and APRO have announced a close collaboration in 3 different oncology clinical trials to test new treatment strategies given in an innovative way. The 3 trials have been…
Read More...

Forendo Pharma, a drug development company focusing on novel oral treatments for endometriosis patients, announces that it has received clinical trial authorisation (CTA) from the UK's…
Read More...

Theratechnologies Inc. announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-vial formulation of EGRIFTA.…
Read More...

Treating advanced breast cancer with three drugs instead of one could boost the effectiveness of treatment and stop tumours developing resistance, a new study reports. Researchers…
Read More...

Recipharm has announced the launch of its standalone serialisation service ahead of the introduction of the EU Falsified Medicines Directive (FMD). The new service is designed to…
Read More...

A. Menarini Asia-Pacific Holdings Pte Ltd, a member of the Italian largest biopharmaceutical company Menarini Group, and Orion Corporation have signed a multi-year licensing agreement…
Read More...

Merz North America announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN (incobotulinumtoxinA) for the…
Read More...

Evotec AG announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious…
Read More...

Sanofi is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in Chengdu, Sichuan province, China. The new R&D operations hub…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has…
Read More...